Siva Therapeutics is developing a simple, safe, and effective adjunct cancer treatment termed Targeted Hyperthermia™, which generates therapeutic heat emanating from within solid tumors using systemically injected precision gold nanorods and an infrared light engine – technology termed photothermal therapy. Heat has several beneficial effects for solid tumors, including selective induction of apoptosis in cancer cells, stimulation of the immune system, inactivation of cancer stem cells, and increased perfusion resulting in improved drug efficacy. Targeted Hyperthermia provides precision heating of tumors with minimal collateral damage, using SivaRods™ polymer-coated gold nanorods and a SivaLum™ infrared light engine, and it promises to be a valuable adjunct to current drug therapies. While awareness of the therapeutic value of hyperthermia has been in the cancer community for many decades, implementing practical, safe, and cost effective hyperthermic therapies has been challenging. Nanotechnology has provided key tools for targeting heat to tumors, and photohermal therapy, in particular, has demonstrated efficacy, both in animal models, and now in the clinic. A critical hurdle for photothermal therapy has been scaling up manufacture of nanoparticles to pilot batch size, while maintaining plasmonic properties and uniformity of the material. Siva has accomplished pilot scale manufacturing, and is currently undertaking full characterization of this material through a grant from the Nanotechnology Characterization Laboratory (https://ncl.cancer.gov/), which is supported by the National Cancer Institute, the FDA, and NIST. Additionally, Siva is developing a second generation LED-based infrared light engine with the ability to illuminate regions of ~10 cm in diameter with high intensity infrared light to excite nanorods that have concentrated in tumors. Together, these advances have made nanotechnology-enabled photothermal therapy more practical, safe, and cost-effective than was previously possible.